CEACAM5 is glycoprotein that rarely expressed in normal adult tissues, but overexpressed in multiple solid tumors, including NSCLC.248 The preclinical activity of SAR-408701 was investigated and results showed a promising potential therapeutic candidate for CEACAM5 positive cancer.249 The safety and efficacy of SAR-408701 was examined in an open-label, dose-escalation, dose-expansion phase 1 study (NCT02187848). The gene discussed is CEACAM5; the disease is cancer.